Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing

Vector Science & Therapeutics (TSXV: PAIN) ("Vector" or the "Company") today announced it has entered into an option agreement to purchase up to a 15% equity interest in LyoGenesis Plus for cash ...

Vector Science and Therapeutics Announces Listing on the TSX Venture Exchange

Canadian Public Market Listing Positions Vector Science and Therapeutics to Advance Biomechanical and Localized Drug Delivery Innovation. Vancouver, British Columbia--(Newsfile Co ...
Newswire

Vector Science & Therapeutics Appoints Tabitha Hendren as Director, Engineering and Design

LODI, Wis., Oct. 2, 2025 /CNW/ -- Vector Science & Therapeutics today announced the appointment of Tabitha Hendren as Director, Engineering and Design. Hendren will report to Chief Technology Officer ...
Wall Street Journal

Vector Science & Therapeutics Corp.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

/C O R R E C T I O N -- Vector Sciences & Therapeutics/

In the news release, Vector Science & Therapeutics Enters Three-Year Development and Manufacturing Agreement with MPP Group ...
BizTimes

Vector Science & Therapeutics agrees to option to invest in LyoGenesis Plus, gaining access to FDA-registered manufacturing facility

Credit: Google Street View MPP Group LLC's facility in Mequon. Subscribe to BizTimes Daily – Local news about the people, companies and issues that impact business in Milwaukee and Southeast Wisconsin ...